Latest Hedgehog signaling pathway Stories
A UCLA study has identified a way to turn off a key signaling pathway involved in physiological processes that can also stimulate the development of cancer and other diseases. The findings may lead to new treatments and targeted drugs using this approach.In the study, which is currently available in the online edition of the journal Molecular Endocrinology, scientists found that by activating a receptor in cells called the liver X receptor (LXR), they were able to inhibit the hedgehog (Hh)...
A new study reveals the genetic foundation of what causes lung cancer to quickly spread.Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) found the same cellular pathway involved in the spread of colorectal cancer is also responsible for providing lung cancer with a better ability to get into and take over other organs without delay and with little need to adapt to its new environment.Researchers looked at large collections of lung tumor samples and found a pathway called the WNT...
A new study by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone "“ the two most prominent sites of lung cancer relapse. The study will be published online in the journal Cell on July 2.Researchers discovered that the same cellular pathway that has been shown to be involved with the spread of colorectal cancer is also responsible for providing lung cancer...
A researcher of the University of Innsbruck elucidates an important developmental mechanismIt is the concentration of a few signaling molecules that determines the fate of individual cells during the early development of organisms. In the renowned journal Current Biology, a team of molecular biologists led by Pia Aanstad of the University of Innsbruck reports that a variety of molecular mechanisms accounts for the interpretation of the concentration of the signaling molecule Hedgehog.The...
Researchers at Worcester Polytechnic Institute have identified the function of a protein that sticks out of the embryonic cell membrane like an antenna and processes signals needed for proper wing development in fruit fliesIn their ongoing study of the processes involved in embryonic development in fruit flies, researchers at WPI's Life Sciences and Bioengineering Center at Gateway Park have identified the function of a protein that sticks out of the embryonic cell membrane like an antenna...
U.S. researchers said brain tumors appear to more aggressive when they feed off cancer stem cells that use Sonic Hedgehog protein signaling mechanisms. The researchers said the finding could help in the development of treatments that kill malignant brain tumors at their source and prevent them from recurring, Cedars-Sinai Medical Center said Monday. The study, conducted by Cedars Sinai's Maxine Dunitz Neurosurgical Institute, identified a subset of brain tumor stem cells that are dependent...
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 7th Annual BIO Investor Forum Conference, at 3:45 p.m. local time (6:45 p.m. EDT) on October 30, 2008, at the Palace Hotel in San Francisco, California. Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an...
Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its second quarter financial results on Tuesday, October 28, 2008 before the market opens. The Company will also hold a conference call on the same day at 10:00 A.M. Eastern time to discuss: (i) its Hedgehog antagonist program under collaboration with Genentech, (ii) CUDC-101, CUDC-305 and other proprietary...
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 2008 Boston Biotech R&D Conference, at 9:00 a.m. EDT on October 22, 2008, at Harvard Medical School in Cambridge, Mass. Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule...
CAMBRIDGE, Mass., Oct. 16, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its oral Hedgehog signaling pathway inhibitor, IPI-926, in patients with advanced and/or metastatic solid tumors. IPI-926 is a novel, proprietary inhibitor of the Hedgehog signaling pathway. It is a derivative of the natural product cyclopamine that binds to and inhibits...
